期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗原致敏DC联合CIK细胞对肺癌细胞杀伤作用的研究 被引量：3

Effect of Dendritic Cells Combined with Cytokine-induced Killer Cells on Cytotoxicity against Lung Cancer Cells
暂未订购
导出
摘要 [目的]研究肿瘤抗原致敏的树突状细胞(DC)联合细胞因子诱导的杀伤细胞(CIK)对肺腺癌原代细胞的杀伤作用,及肺癌细胞杀伤作用中细胞因子水平。[方法]取健康人外周血单个核细胞(PBMNC),常规诱导出DC、CIK、LAK细胞;用肺癌A549细胞提取的肿瘤抗原冲击DC,倒置显微镜下观察DC形态,流式细胞仪检测DC经抗原冲击和未经抗原冲击后其表型变化;把CIK细胞、DC-CIK细胞、LAK细胞和DC-LAK细胞作为效应细胞,肺腺癌原代细胞作为靶细胞,共分为4组,在10∶1、20∶1、50∶1的效靶比时,进行杀伤试验,使用LDH释放法测定杀伤活性;ELISA法检测杀伤试验中细胞因子IL-2、IL-12、IFN-γ的分泌水平。[结果]DC经肿瘤抗原冲击后在镜下呈典型成熟形态;DC-CIK细胞对肺腺癌原代细胞的杀伤活性高于CIK细胞、LAK细胞和DC-LAK细胞(P<0.05),随着效靶比的升高,DC-CIK细胞对肺癌细胞的杀伤效应随之增强(P<0.05);细胞杀伤试验中DC-CIK细胞组中IFN-γ、IL-12的分泌量明显高于其它3组(P<0.05);而IL-2的分泌量以DC-LAK细胞组为最高,DC-LAK和LAK细胞组明显高于其他2组(P<0.05)。[结论]肿瘤抗原致敏的DC可诱导特异性CIK细胞,显著提高CIK细胞对肺腺癌原代细胞的杀伤作用,其杀伤作用可能与IFN-γ、IL-12的分泌量有关。
作者 李可 吕章春 陈海祥 张立煌
机构地区 永康市第一人民医院 浙江大学医学院免疫研究所
出处 《中国肿瘤》 CAS 2008年第5期417-420,共4页 China Cancer
基金 浙江省科技计划项目(2005C33018)
关键词 树突状细胞 细胞因子 肺腺癌原代细胞 杀伤作用
分类号 R730.2 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Clegg A,Scott DA,Sidhu M,et al.A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel,docetaxel,gemcitabine and vinorelbine in non-small-cell lung cancer[J].Health Technol Assess,2001,5(32):1-195.
  • 2Schmidt-Wolf IG,Lefterova P,Johnston V,et al.Sensitivity of multidrug resistant tumor cell lines to immunologic effector cells[J].Cell Immunol,1996,169(1):85-90.
  • 3Shi Y,Yu J,Cen X,et al.Large-capacity expanded cytokineinduced killer cells and its cytotoxic activity[J].Sheng Wu Yi Xue Gong Cheng Xue Za Zhi,2001,18(1):94-96.
  • 4Carlens S,Gilljam M,Chambers BJ,et al.A new method for in vitro expansion of cytotoxic human an CD3-CD56+ nature killer cells[J].Hum Immunol,2001,62(10):1092-1098.
  • 5Derek N,Hart J.Dentritic cell:unqiue leukocyte population which control the primary immune response[J].Blood,1997,90(9):3245-3287.
  • 6鄂征.组织培养和分子细胞技术[M].北京:北京出版社,1994.
  • 7杨新静,黄建安,朱一蓓,胡玉敏,闫廷赞,张学光.CIK细胞对肺腺癌细胞株A549体内外杀瘤活性的实验研究[J].苏州大学学报（医学版）,2006,26(4):553-555. 被引量：6
  • 8Maki G.Ex vivo purging of stem cell autografts using cytotoxic cells[J].J Hematother Stem Cell Res,2001,10(4):545-551.
  • 9Alvarnas JC,Linn YC,Hope EG,et al.Expansion of cytotoxic CD3+CD56+cells from peripheral blood progenitor cells of patients under going autologous hematopoietic cell transplantation[J].Biol Blood Marrow Transplant,2001,7(4):216-222.
  • 10Hongengs S,Petvises S,Worapongpaiboon S,et al.Generation of CD3+CD56+ cytokine induced killer cells and their in vitro cytotoxicity against pediatric cancer cells[J].Int J Hematol,2003,77(2):175-179.

二级参考文献9

  • 1Schmidt-Wolf IG,Lefterova P,Johnston V,et al.Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells.Cell Immunol,1996,169:85-90.
  • 2Marten A,Schttker B,Ziske C,et al.Increase of the immunostimulatory effect of dendriticcells by pulsing with CA19-9 protein[J].Immunother,2000,23:464-472.
  • 3Schmidt Wolf IGH,Lefterova P,Johnston V,et al.Sensitivity of multidrug resistant tumor cell lines to immunologic effector cells[J].Cell Immunol,1996,169:85-90.
  • 4Verneris MR,Kornacker M,Mailander V,et al.Resistance of ex vivo expanded CD3^+ CD56+ T cells to Fas mediated apoptosis[J].Cancer Immunol Immunother,2000,49:335-345.
  • 5Marten A,Ziske C,Schttker B,et al.Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both populations[J].Immunother,2001,24:502-510.
  • 6Schmidt-Wolf Ig,Finke S,Trojaneck B,et al.PhaseI clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer,colorectal cancer and lymphoma[J].Br J Cancer,1999,81:1009-1016.
  • 7Finke S,Trojaneck B,Lefterova P,et al.Increase of proliferation rate and enhancement of antitumor cytotoxicity of expanded human CD3^+CD56^+ immunologic effector cells by receptor-mediated transfection with the interleukin-7 gene[J].Gene Ther,1998,5:31-39.
  • 8Flieger D,Kufer P,Beier I,et al.A bispecific single-chain antibody directed against EpCAM/CD3 in combination with the cytokines interferon alpha and interleukin-2 efficiently retargets T and CD3^+CD56^+ natural-killer-like T lymphocytes to EpCAM-expressing tumor cells[J].Cancer Immunol Immunother,2000,49:441-448.
  • 9任欢,邢淑贤,徐红薇,宋英晖,商晓舟,周贵生,田景先,李殿俊.CIK的体外增殖及体内外杀瘤活性的实验研究[J].中国肿瘤生物治疗杂志,1999,6(1):17-21. 被引量：66

共引文献5

同被引文献30

  • 1陈爱琴,林慧.树突状细胞疫苗治疗恶性肿瘤病人的观察和护理[J].现代护理,2005,11(16):1310-1310. 被引量：5
  • 2谢裕安.树突状细胞与细胞因子诱导杀伤细胞治疗肿瘤研究进展[J].中国肿瘤,2005,14(10):663-666. 被引量：14
  • 3陆勤美,施玲燕,徐鸣.恶性肿瘤的CIK细胞治疗及护理[J].中国交通医学杂志,2005,19(4):417-418. 被引量：10
  • 4Kim H M, Kang J S, Lim J, et al. Inhibition of human ovarian tumor growth by eytokine-induced killer cells [ J ]. Arch Pharm Res, 2007, 30( 11 ):1464-1470.
  • 5Schmidt-Wolf I G, Negrin R S, Kiem H P, et al. Use of a SCID mouse/human lymphoma model to evaluate cytokine- induced killer cells with potent antitumor cell activity [ J ]. J Exp Med, 1991, 174( 1 ) :139-149.
  • 6Marten A, Ziske C, Schottker B. Interactions between dendritic cells and cytokine-induced killer cells lead to an activation of both population [ J ]. J Ivamunother, 2001, 24 (6) :502-510.
  • 7Emens L A, Reilly R T, Jaffee E M. Breast cancer vaccines:maximizing cancer treatmnet by tapping into host immunity[ J ]. Endocrine-Related Cancer, 2005, 12 ( 1 ) : 1- 17.
  • 8Ovali E, Dikmen T, Sonmez M, et al. Active immunotherapy for cancer patients using tumor lysate pulsed dendritic cell vaccine:a safety study [ J ]. J Exp Clin Cancer Res, 2007, 26(2) :209-214.
  • 9Schmidt J, Klempp C, Buchler M W, et al. Release of iC3b from apoptotic tumor cells induces tolerance by binding to immature dendritic cells in vitro and in vivo [ J ]. Cancer Immunol Immunother, 2006, 55 (1) :31-38.
  • 10李世俊,张连生,柴晔,张玉芳,张彦明,曾鹏云,吴重阳.树突状细胞与细胞因子诱导的杀伤细胞共培养对多药耐药肿瘤细胞系的杀伤活性[J].中华肿瘤杂志,2007,29(10):733-737. 被引量：25

引证文献3

二级引证文献1

中国肿瘤
2008年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部